Literature DB >> 23464724

Primaquine for radical cure of Plasmodium vivax and Plasmodium ovale malaria: an observational survey (2008-2010).

Jean-François Faucher1, Anne-Pauline Bellanger, Catherine Chirouze, Laurent Hustache-Mathieu, Sandrine Genton, Bruno Hoen.   

Abstract

Since 2008, the French guidelines have promoted the systematic use of 30 mg/day of primaquine for the radical cure of Plasmodium vivax and Plamodium ovale infections. We observed three relapses in 10 patients with P vivax acquired in French Guiana. No relapses were seen in West African P ovale patients.
© 2013 International Society of Travel Medicine.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23464724     DOI: 10.1111/jtm.12009

Source DB:  PubMed          Journal:  J Travel Med        ISSN: 1195-1982            Impact factor:   8.490


  3 in total

1.  Antirelapse Efficacy of Various Primaquine Regimens for Plasmodium vivax.

Authors:  D D Rajgor; N J Gogtay; V S Kadam; M M Kocharekar; M S Parulekar; S S Dalvi; A B Vaidya; N A Kshirsagar
Journal:  Malar Res Treat       Date:  2014-09-10

2.  Prevention measures and socio-economic development result in a decrease in malaria in Hainan, China.

Authors:  Shan-Qing Wang; Yu-Chun Li; Zhi-Ming Zhang; Guang-Ze Wang; Xi-Min Hu; Whitney A Qualls; Rui-De Xue
Journal:  Malar J       Date:  2014-09-15       Impact factor: 2.979

Review 3.  Guidance for Using Tafenoquine for Prevention and Antirelapse Therapy for Malaria - United States, 2019.

Authors:  Julia C Haston; Jimee Hwang; Kathrine R Tan
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2019-11-22       Impact factor: 17.586

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.